Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 Jul;3(4):512-21.
doi: 10.1161/CIRCHEARTFAILURE.109.900282. Epub 2010 May 13.

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

Siva Bhashyam  1 , Anjali V Fields, Brandy Patterson, Jeffrey M Testani, Li Chen, You-Tang Shen, Richard P Shannon
Affiliations
Comparative Study

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

Siva Bhashyam et al. Circ Heart Fail. 2010 Jul.

Abstract

Background: We have shown that glucagon-like peptide-1 (GLP-1[7-36] amide) stimulates myocardial glucose uptake in dilated cardiomyopathy (DCM) independent of an insulinotropic effect. The cellular mechanisms of GLP-1-induced myocardial glucose uptake are unknown.

Methods and results: Myocardial substrates and glucoregulatory hormones were measured in conscious, chronically instrumented dogs at control (n=6), DCM (n=9) and DCM after treatment with a 48-hour infusion of GLP-1 (7-36) amide (n=9) or vehicle (n=6). GLP-1 receptors and cellular pathways implicated in myocardial glucose uptake were measured in sarcolemmal membranes harvested from the 4 groups. GLP-1 stimulated myocardial glucose uptake (DCM: 20+/-7 nmol/min/g; DCM+GLP-1: 61+/-12 nmol/min/g; P=0.001) independent of increased plasma insulin levels. The GLP-1 receptors were upregulated in the sarcolemmal membranes (control: 98+/-2 density units; DCM: 256+/-58 density units; P=0.046) and were expressed in their activated (65 kDa) form in DCM. The GLP-1-induced increases in myocardial glucose uptake did not involve adenylyl cyclase or Akt activation but was associated with marked increases in p38alpha MAP kinase activity (DCM+vehicle: 97+/-22 pmol ATP/mg/min; DCM+GLP-1: 170+/-36 pmol ATP/mg/min; P=0.051), induction of nitric oxide synthase 2 (DCM+vehicle: 151+/-13 density units; DCM+GLP-1: 306+/-12 density units; P=0.001), and GLUT-1 translocation (DCM+vehicle: 21+/-3% membrane bound; DCM+GLP-1: 39+/-3% membrane bound; P=0.005). The effects of GLP-1 on myocardial glucose uptake were blocked by pretreatment with the p38alpha MAP kinase inhibitor or the nonspecific nitric oxide synthase inhibitor nitro-l-arginine.

Conclusions: GLP-1 stimulates myocardial glucose uptake through a non-Akt-1-dependent mechanism by activating cellular pathways that have been identified in mediating chronic hibernation and the late phase of ischemic preconditioning.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The sarcolemmal expression of GLP-1 receptor isoforms (Figure 1A) and basal and agonist stimulated myocardial adenylyl cyclase activity (Figure 1B) in Control dogs (n=6), DCM alone (n=6), DCM+Veh (n=6) and DCM+GLP-1 (n=6). * p=0.046 Control compared to DCM
Figure 2
Figure 2
Akt-1 protein expression and activation as measured by serine 473 phosphorylation in Control dogs (n=6), DCM alone (n=9), DCM+Veh (n=6) and DCM+GLP-1 (n=9). One way ANOVA, p=0.001. * p=0.003 Control compared to DCM
Figure 3
Figure 3
GLUT–4 and GLUT–1 translocation in response to GLP-1 treatment in Control dogs (n=6), DCM alone (n=9), DCM+Veh (n=6) and DCM+GLP-1 (n=9). Transporter translocation is expressed as the % membrane bound/total transporter concentration in membrane and cytosolic fractions. One way ANOVA p=0.0013 for GLUT-1. **p=0.0013 DCM+ Veh compared to DCM+GLP-1.
Figure 4
Figure 4
The effects of GLP-1 treatment on AMP kinase protein expression (4A) and activity (4B) in Control dogs (n=6), DCM alone (n=9), DCM+Veh (n=6) and DCM+GLP-1 (n=9). One way ANOVA for AMP kinase activity p=0.0590. *p=0.0181 Control compared to DCM.
Figure 5
Figure 5
The effects of GLP-1 treatment on p38α MAP kinase expression (5A) and activity (5B) in Control dogs (n=6), DCM alone (n=9), DCM+Veh (n=6) and DCM+GLP-1 (n=9). One way ANOVA p=0.2869 for p38 MAP kinase activity. **p=0.0431 DCM+ Veh compared to DCM+GLP-1.
Figure 6
Figure 6
The effects of GLP-1 treatment on myocardial NOS isoform expression (6A) and on myocardial NO uptake (6B) in Control dogs (n=6), DCM alone (n=9), DCM+Veh (n=6) and DCM+GLP-1 (n=9). One way ANOVA NOS1 p=0.0111, NOS2 p=0.0002; NOS3 p=0.4371. One way ANOVA NO uptake p=0.0001. *p=0.0042 Control compared to DCM. ** **p=0.0010 DCM+ Veh compared to DCM+GLP-1.
Figure 7
Figure 7
The effects of p38 MAP kinase inhibition with SB 203580 (7A) and NOS inhibition with nitro L-arginine (N-LA; 7B) on GLP-1 mediated myocardial glucose uptake in Control (n=6) and DCM (n=6). *p<0.02 GLP-1 compared to Blockade +GLP-1
Figure 8
Figure 8
The effects of GLP-1 treatment on mitochondrial protein expression (8A) and lipid peroxidation (8B) in Control dogs (n=5), DCM alone (n=5), DCM+Veh (n=4) and DCM+GLP-1 (n=5). mCO = mitochrondrial cytochrome oxidase; SDH = succinate dehydrogenase;UCP-3 = uncoupling protein-3, Mn SOD= manganese superoxide dismutase. One way ANOVA MCO p=0.001; SDH p=0.001; UCP-3 p=0.001; MnSOD p=0.00
Figure 8
Figure 8
The effects of GLP-1 treatment on mitochondrial protein expression (8A) and lipid peroxidation (8B) in Control dogs (n=5), DCM alone (n=5), DCM+Veh (n=4) and DCM+GLP-1 (n=5). mCO = mitochrondrial cytochrome oxidase; SDH = succinate dehydrogenase;UCP-3 = uncoupling protein-3, Mn SOD= manganese superoxide dismutase. One way ANOVA MCO p=0.001; SDH p=0.001; UCP-3 p=0.001; MnSOD p=0.00
See this image and copyright information in PMC

References

    1. Drucker DJ. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Curr Pharm Des. 2001;7:1399. - PubMed
    1. Perfetti R, Merkel P. Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur J Endocrinol. 2000;143:717–25. - PubMed
    1. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res. 2001;56:377–99. - PubMed
    1. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199–206. - PubMed
    1. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002;51:S434–42. - PubMed

Publication types

MeSH terms